These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16623112)

  • 21. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
    van der Putten K; Braam B; Jie KE; Gaillard CA
    Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of anemia correction on cardiovascular disease in end-stage renal disease.
    Murphy ST; Parfrey PS
    Semin Nephrol; 2000 Jul; 20(4):350-5. PubMed ID: 10928337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypertension, atherosclerosis and kidney].
    Zuccalà A; Fiorenza S; Rapanà R; Santoro A
    G Ital Nefrol; 2005; 22 Suppl 31():S9-14. PubMed ID: 15786409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
    Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
    Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The cardio-renal anemia syndrome: what is it? With a focus on congestive heart failure].
    Petersen H; Jensen KE; Haghfelt TH
    Ugeskr Laeger; 2006 May; 168(19):1864-7. PubMed ID: 16756804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia and chronic heart failure implications and treatment options.
    Anand IS
    J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy insight: management of cardiovascular disease in the renal transplant recipient.
    Rigatto C; Parfrey P
    Nat Clin Pract Nephrol; 2006 Sep; 2(9):514-26. PubMed ID: 16941044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients.
    Fernandez-Fresnedo G; Rodrigo E; de Francisco AL; de Castro SS; Castañeda O; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S246-9. PubMed ID: 17130269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI; Zueva EB; Silverberg DS; Shaked M
    J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Past, present, and future of chronic kidney disease anemia management in the United States.
    Wish JB
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anemia, renal transplantation, and the anemia paradox.
    Rigatto C
    Semin Nephrol; 2006 Jul; 26(4):307-12. PubMed ID: 16949469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antioxidants, carnitine and erythropoietin].
    Calò LA; Bertipaglia L; Pagnin E
    G Ital Nefrol; 2006; 23 Suppl 34():S47-50. PubMed ID: 16633995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaemia in heart failure: a common interaction with renal insufficiency called the cardio-renal anaemia syndrome.
    Palazzuoli A; Gallotta M; Iovine F; Nuti R; Silverberg DS
    Int J Clin Pract; 2008 Feb; 62(2):281-6. PubMed ID: 18081797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart and iron deficiency anaemia in rats with renal insufficiency: the role of hepcidin.
    Toblli JE; Cao G; Rivas C; Kulaksiz H
    Nephrology (Carlton); 2008 Oct; 13(7):636-45. PubMed ID: 18808386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anemia: the point of convergence or divergence for kidney disease and heart failure?
    Kazory A; Ross EA
    J Am Coll Cardiol; 2009 Feb; 53(8):639-47. PubMed ID: 19232895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiology of anemia in patients with advanced heart failure.
    Nanas JN; Matsouka C; Karageorgopoulos D; Leonti A; Tsolakis E; Drakos SG; Tsagalou EP; Maroulidis GD; Alexopoulos GP; Kanakakis JE; Anastasiou-Nana MI
    J Am Coll Cardiol; 2006 Dec; 48(12):2485-9. PubMed ID: 17174186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.